Evaluation of CYP2C19 Gene Polymorphisms in Patients with Acid Peptic Disorders Treated with Esomeprazole

References

• Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2(3):295–314. doi:10.1586/ecp.09.8
   PubMedGoogle Scholar
• Cardona-Ospina JA, Medina-Morales DA, Rodr?guez-Morales AJ, Machado-Alba JE. Efectos adversos a largo plazo de los inhibidores de la bomba de protones. Perspectiva desde la medicina basada en la evidencia. Rev Colomb Gastroenterol. 2016;31:403–408. doi:10.22516/25007440.115
   Google Scholar
• Donato MT 1. ¿Qué es el citocromo P-450 y cómo funciona? Maria Teresa Donato Martín. 2000:29–62.
   Google Scholar
• Hunt SE, McLaren W, Gil L, et al. Ensembl variation resources. Database. 2018;2018.
   PubMedGoogle Scholar
• Guengerich FP, Rendic S. Update information on drug metabolism systems— 2009, part I. Curr Drug Metab. 2010;11:1–3. doi:10.2174/138920010791110908
   PubMed Web of Science ®Google Scholar
• Zhang H-F, Wang -H-H, Gao N, et al. Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomess. J Pharmacol Exp Ther. 2016;358(1):83–93. doi:10.1124/jpet.116.233635
   PubMed Web of Science ®Google Scholar
• Ph. D. Lemke TL, Ph. D. Williams DA, Ph. D. Roche VF, Ph. D. Zito SW, eds. Foye’s Principles of Medicinal Chemistry. Vol. 106. 2013. doi:10.1023/B:PRES.0000030927.38007.36
   Google Scholar
• Hiratsuka M. Genetic polymorphisms and in vitro functional characterization of CYP2C8, CYP2C9, and CYP2C19 allelic variants. Biol Pharm Bull. 2016;39(11):1748–1759. doi:10.1248/bpb.b16-00605
   PubMed Web of Science ®Google Scholar
• Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013;17(3):165–184. doi:10.1007/s40291-013-0028-5
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Ingelman-Sundberg M, Miller NA, et al. The Pharmacogene Variation (PharmVar) consortium: incorporation of the human Cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 2018;103(3):399–401. doi:10.1002/cpt.910
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Marjani A. Genetic variations in cytochrome P450 2C9 and 2C19: a review. Curr Pharmacogenomics Person Med. 2016;14:18–28. doi:10.2174/1875692115666161214152223
   Google Scholar
• Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2020. doi:10.1002/cpt.2015
   Web of Science ®Google Scholar
• Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95(1):2–8. doi:10.1111/j.1600-0773.2004.pto950102.x
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol. 2008;21:70–83. doi:10.1021/tx700079z
   PubMed Web of Science ®Google Scholar
• Kamiya C, Inui N, Hakamata A, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci. 2019;139:361–366. doi:10.1016/j.jphs.2019.03.001
   PubMed Web of Science ®Google Scholar
• Velazquez MNR, Parween S, Udhane SS, Pandey AV. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase. Biochem Biophys Res Commun. 2019;515(1):133–138. doi:10.1016/j.bbrc.2019.05.127
   PubMed Web of Science ®Google Scholar
• Tunthong R, Sukasem C, Puangpetch A, et al. Pharmacogenetic study of CYP2C19 variation and clopidogrel dose adjustment according to platelet reactivity monitoring in atherothromboticrisk patients in Thailand. Curr Pharmacogenomics Person Med. 2013;11:154–161. doi:10.2174/1875692111311020007
   Google Scholar
• Cattaneo D, Perico N, Remuzzi G. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am J Transplant. 2004;4:299–310. doi:10.1111/j.1600-6143.2004.00312.x
   PubMed Web of Science ®Google Scholar
• Daly AK, Cascorbi I. Opportunities and limitations: the value of pharmacogenetics in clinical practice. Br J Clin Pharmacol. 2014;77:583–586. doi:10.1111/bcp.12354
   Web of Science ®Google Scholar
• Ur Rehman K, Akhtar T, Sabar MF, Tariq MA. Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients. Exp Ther Med. 2015;10:309–315. doi:10.1124/dmd.32.8.821
   Web of Science ®Google Scholar
• Zhong Z, Hou J, Li B, et al. Analysis of CYP2C19 genetic polymorphism in a large ethnic hakka population in southern China. Med Sci Monit. 2017;23:6186–6192. doi:10.12659/MSM.905337
   PubMed Web of Science ®Google Scholar
• Heredia MM, Araujo D, Rodríguez M, Sierra E. Genotypic and fenotypic characterization of CYP2C19 from a mestiza population in Colombia. Clin Chem Lab Med. 2015;53:S770.
   Google Scholar
• Isaza C, Henao J, Isaza Martínez JH, Sepúlveda Arias JC, Beltrán L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo nidividuals. BMC Clin Pharmacol. 2007;7. doi:10.1186/1472-6904-7-6
   Google Scholar
• Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab. 2012;13:1303–1312. doi:10.2174/138920012803341393
   PubMed Web of Science ®Google Scholar
• Bennadi D. Self-medication: a current challenge. J Basic Clin Pharm. 2013;5:19–23. doi:10.4103/0976-0105.128253
   PubMedGoogle Scholar
• Scott SA, Martis S, Peter I, et al. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J. 2012;12(4):297–305. doi:10.1038/tpj.2011.5
   Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821–827.
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013;23:721–728. doi:10.1097/FPC.0b013e3283653b27
   PubMed Web of Science ®Google Scholar
• De Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269(22):15419–15422. doi:10.1016/S0021-9258(17)40694-6
   PubMed Web of Science ®Google Scholar
• Chaudhry AS, Prasad B, Shirasaka Y, et al. The CYP2C19 intron 2 branch point SNP is the ancestral polymorphism contributing to the poor metabolizer phenotype in livers with CYP2C19*35 and CYP2C19*2 alleles. Drug Metab Dispos. 2015;43(8):1226–1235. doi:10.1124/dmd.115.064428
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Gardner EE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90:328–332. doi:10.1038/clpt.2011.132
   PubMed Web of Science ®Google Scholar
• Favela-Mendoza AF, Martinez-cortes G, Hernandez-zaragoza M, et al. Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype. J Genet. 2015;94(1):3–7. doi:10.1007/s12041-015-0477-1
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol. 2008;65:437–439. doi:10.1111/j.1365-2125.2007.03057.x
   PubMed Web of Science ®Google Scholar
• Martis S, Peter I, Hulot J-S, et al. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J. 2013;13(4):369–377. doi:10.1038/tpj.2012.10
   PubMed Web of Science ®Google Scholar
• CLM. IGSR population. Availbale from: https://www.internationalgenome.org/data-portal/population/CLM. Accessed April 8, 2021.
   Google Scholar
• Ardlie KG, Kruglyak L, Seielstad M. Patterns of linkage disequilibrium in the human genome. Nat Rev Genet. 2002;3:299–309. doi:10.1038/nrg777
   PubMed Web of Science ®Google Scholar
• Bush WS, Moore JH, Lewitter F, Kann M. Chapter 11: genome-wide association studies. PLoS Comput Biol. 2012;8(12):e1002822. doi:10.1371/journal.pcbi.1002822
   PubMed Web of Science ®Google Scholar
• Dean L. Diazepam therapy and CYP2C19 genotype. In: Pratt VM, editor. Medical Genetics Summaries. US: National Center for Biotechnology Information; 2012.
   Google Scholar
• Langaee TY, Zhu H-J, Wang X, et al. The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping. Pharmacogenet Genomics. 2014;24(8):381–386. doi:10.1097/FPC.0000000000000068
   Web of Science ®Google Scholar
• Zhang L, Sarangi V, Moon I, et al. CYP2C9 and CYP2C19: deep mutational scanning and functional characterization of genomic missense variants. Clin Transl Sci. 2020;13(4):727–742. doi:10.1111/cts.12758
   PubMed Web of Science ®Google Scholar
• El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447–460. doi:10.1080/17425255.2018.1461835
   PubMed Web of Science ®Google Scholar
• Bhise NS, Elsayed AH, Cao X, Pounds S, Lamba JK. MicroRNAs mediated regulation of expression of nucleoside analog pathway genes in acute myeloid leukemia. Genes. 2019;10(4):319. doi:10.3390/genes10040319
   Web of Science ®Google Scholar
• Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. doi:10.1038/nature15817
   PubMed Web of Science ®Google Scholar
• Rojas CA, Sepúlveda Copete M, García Abadía JA, et al. Un ensayo clínico piloto de la efectividad clínica de dos presentaciones de esomeprazol. Rev Colomb Gastroenterol. 2019;34(3):261–268. doi:10.22516/25007440.335
   Google Scholar
• Dong Y, Xiao H, Wang Q, et al. Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray. Int J Clin Exp Med. 2015;8(10):18917–18926.
   Web of Science ®Google Scholar
• Ye C, Jin H, Zhang R, et al. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients. J Int Med Res. 2014;42(1):67–76. doi:10.1177/0300060513499094
   Web of Science ®Google Scholar
• Al-Jenoobi FI, Alkharfy KM, Alghamdi AM, et al. CYP2C19 genetic polymorphism in Saudi Arabians. Basic Clin Pharmacol Toxicol. 2013;112(1):50–54. doi:10.1111/j.1742-7843.2012.00919.x
   PubMed Web of Science ®Google Scholar